SCHEMBL26885183

SCHEMBL26885183

CC(C)NC(=O)c1ccc2c(O)cc([N+](=O)[O-])cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ CYP1A2 P05177 1/20 0.46
▸ HTT P42858 3/20 0.46
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ ERN1 O75460 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PPARG P37231 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ PABPC1 P11940 1/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ PTPN5 P54829 1/20 0.38
▸ PTPN11 Q06124 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26885193 0.90 LMNA (0.49) LMNASMN1; SMN2POLBCYP1A2HTT
SCHEMBL26885172 0.82 LMNA (0.61) LMNASMN1; SMN2POLBCYP1A2HTT
SCHEMBL26885176 0.81 SMN1; SMN2 (0.60) LMNASMN1; SMN2POLBCYP1A2HTT
SCHEMBL26885089 0.80 ERN1 (0.44) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL26886781 0.80 XDH (0.47) LMNAPOLBCYP1A2ALDH1A1ERN1
SCHEMBL26885081 0.80 SMN1; SMN2 (0.49) LMNASMN1; SMN2POLBCYP1A2HTT
SCHEMBL26886782 0.79 LCK (0.51) LMNASMN1; SMN2POLBHTTMEN1
SCHEMBL4488971 0.76 RAB9A (0.62) LMNASMN1; SMN2POLBHTTMEN1
SCHEMBL3071601 0.76 MEN1 (0.56) LMNASMN1; SMN2POLBCYP1A2MEN1
SCHEMBL26886020 0.75 CASP6 (0.56) MEN1KMT2AALDH1A1ERN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381159-A1 SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF UNIVERSITY OF MIAMI 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381159-A1 SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF ACE2, ACE, SARS1 LMNA 2523/4885SMN1; SMN2 4878/4885POLB 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback